Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular basis of the anti-cancer effect of Huaier
jRCT1091220335Recruiting
- Sponsor
- Bradeion Institute of Medical Sciences
- Start
- Mar 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of huaier granule in hepatocellular carcinoma (HCC), breast cancer, colorectal cancer (CRC) and 5 more, sponsored by Bradeion Institute of Medical Sciences. Primary endpoints: mRNA expression profiling and pathway analysis and Small RNA (including miRNA) profiling and pathway analysis. Started Mar 2018; status: recruiting.
02
Drugs
huaier granule
03
Conditions
hepatocellular carcinoma (HCC)breast cancercolorectal cancer (CRC)gastrointestinal cancergenitourinary cancer
Beyond the preview
Go deeper on jRCT1091220335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1091220335.